Neoadjuvant Chemotherapy and Ipilimumab For Stage II-IIIA Non-Small Cell Lung Cancer
Objective of this Therapy Area Insight Immune therapy is increasingly becoming an effective treatment for non-small cell lung cancer (NSCLC). The Objective of this study is to determine the percentage of early stage NSCLC patients with detectable circulating T cells specific against tumor-associated antigen (TAA) after receiving platinum based neoadjuvant chemotherapy plus ipilimumab before surgery.…
